The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Hereditary Angioedema Drug-Global Market Insights and Sales Trends 2025

Hereditary Angioedema Drug-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1808094

No of Pages : 92

Ask Your Query
Synopsis
In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.
The global Hereditary Angioedema Drug market size is expected to reach US$ 1145.6 million by 2029, growing at a CAGR of 6.8% from 2023 to 2029. The market is mainly driven by the significant applications of Hereditary Angioedema Drug in various end use industries. The expanding demands from the Retail Pharmacies, Hospital Pharmacies and Online Pharmacies,, are propelling Hereditary Angioedema Drug market. C1 Esterase Inhibitor, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Kallikrein Inhibitor segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hereditary Angioedema Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hereditary Angioedema Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hereditary Angioedema Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hereditary Angioedema Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hereditary Angioedema Drug covered in this report include Pharming Group NV, Takeda, CSL Limited, IBio Inc., BioCryst Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc., etc.
The global Hereditary Angioedema Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pharming Group NV
Takeda
CSL Limited
IBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Global Hereditary Angioedema Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hereditary Angioedema Drug market, Segment by Type:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Global Hereditary Angioedema Drug market, by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Hereditary Angioedema Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Hereditary Angioedema Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Hereditary Angioedema Drug Market Overview
1.1 Hereditary Angioedema Drug Product Overview
1.2 Hereditary Angioedema Drug Market Segment by Type
1.2.1 C1 Esterase Inhibitor
1.2.2 Kallikrein Inhibitor
1.2.3 Selective Bradykinin B2 Receptor Antagonist
1.3 Global Hereditary Angioedema Drug Market Size by Type
1.3.1 Global Hereditary Angioedema Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Hereditary Angioedema Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Hereditary Angioedema Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Hereditary Angioedema Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Hereditary Angioedema Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Hereditary Angioedema Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Hereditary Angioedema Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Hereditary Angioedema Drug Sales Breakdown by Type (2018-2023)
2 Global Hereditary Angioedema Drug Market Competition by Company
2.1 Global Top Players by Hereditary Angioedema Drug Sales (2018-2023)
2.2 Global Top Players by Hereditary Angioedema Drug Revenue (2018-2023)
2.3 Global Top Players by Hereditary Angioedema Drug Price (2018-2023)
2.4 Global Top Manufacturers Hereditary Angioedema Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Hereditary Angioedema Drug Market Competitive Situation and Trends
2.5.1 Hereditary Angioedema Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Hereditary Angioedema Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hereditary Angioedema Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Hereditary Angioedema Drug Market
2.8 Key Manufacturers Hereditary Angioedema Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Hereditary Angioedema Drug Status and Outlook by Region
3.1 Global Hereditary Angioedema Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Hereditary Angioedema Drug Historic Market Size by Region
3.2.1 Global Hereditary Angioedema Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Hereditary Angioedema Drug Sales in Value by Region (2018-2023)
3.2.3 Global Hereditary Angioedema Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Hereditary Angioedema Drug Forecasted Market Size by Region
3.3.1 Global Hereditary Angioedema Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Hereditary Angioedema Drug Sales in Value by Region (2024-2029)
3.3.3 Global Hereditary Angioedema Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Hereditary Angioedema Drug by Application
4.1 Hereditary Angioedema Drug Market Segment by Application
4.1.1 Retail Pharmacies
4.1.2 Hospital Pharmacies
4.1.3 Online Pharmacies
4.2 Global Hereditary Angioedema Drug Market Size by Application
4.2.1 Global Hereditary Angioedema Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Hereditary Angioedema Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Hereditary Angioedema Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Hereditary Angioedema Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Hereditary Angioedema Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Hereditary Angioedema Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Hereditary Angioedema Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Hereditary Angioedema Drug Sales Breakdown by Application (2018-2023)
5 North America Hereditary Angioedema Drug by Country
5.1 North America Hereditary Angioedema Drug Historic Market Size by Country
5.1.1 North America Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Hereditary Angioedema Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Hereditary Angioedema Drug Sales in Value by Country (2018-2023)
5.2 North America Hereditary Angioedema Drug Forecasted Market Size by Country
5.2.1 North America Hereditary Angioedema Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Hereditary Angioedema Drug Sales in Value by Country (2024-2029)
6 Europe Hereditary Angioedema Drug by Country
6.1 Europe Hereditary Angioedema Drug Historic Market Size by Country
6.1.1 Europe Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Hereditary Angioedema Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Hereditary Angioedema Drug Sales in Value by Country (2018-2023)
6.2 Europe Hereditary Angioedema Drug Forecasted Market Size by Country
6.2.1 Europe Hereditary Angioedema Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Hereditary Angioedema Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Hereditary Angioedema Drug by Region
7.1 Asia-Pacific Hereditary Angioedema Drug Historic Market Size by Region
7.1.1 Asia-Pacific Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Hereditary Angioedema Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Hereditary Angioedema Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Hereditary Angioedema Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Hereditary Angioedema Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Hereditary Angioedema Drug Sales in Value by Region (2024-2029)
8 Latin America Hereditary Angioedema Drug by Country
8.1 Latin America Hereditary Angioedema Drug Historic Market Size by Country
8.1.1 Latin America Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Hereditary Angioedema Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Hereditary Angioedema Drug Sales in Value by Country (2018-2023)
8.2 Latin America Hereditary Angioedema Drug Forecasted Market Size by Country
8.2.1 Latin America Hereditary Angioedema Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Hereditary Angioedema Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Hereditary Angioedema Drug by Country
9.1 Middle East and Africa Hereditary Angioedema Drug Historic Market Size by Country
9.1.1 Middle East and Africa Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Hereditary Angioedema Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Hereditary Angioedema Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Hereditary Angioedema Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Hereditary Angioedema Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Hereditary Angioedema Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pharming Group NV
10.1.1 Pharming Group NV Company Information
10.1.2 Pharming Group NV Introduction and Business Overview
10.1.3 Pharming Group NV Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pharming Group NV Hereditary Angioedema Drug Products Offered
10.1.5 Pharming Group NV Recent Development
10.2 Takeda
10.2.1 Takeda Company Information
10.2.2 Takeda Introduction and Business Overview
10.2.3 Takeda Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Takeda Hereditary Angioedema Drug Products Offered
10.2.5 Takeda Recent Development
10.3 CSL Limited
10.3.1 CSL Limited Company Information
10.3.2 CSL Limited Introduction and Business Overview
10.3.3 CSL Limited Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 CSL Limited Hereditary Angioedema Drug Products Offered
10.3.5 CSL Limited Recent Development
10.4 IBio Inc.
10.4.1 IBio Inc. Company Information
10.4.2 IBio Inc. Introduction and Business Overview
10.4.3 IBio Inc. Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 IBio Inc. Hereditary Angioedema Drug Products Offered
10.4.5 IBio Inc. Recent Development
10.5 BioCryst Pharmaceuticals, Inc.
10.5.1 BioCryst Pharmaceuticals, Inc. Company Information
10.5.2 BioCryst Pharmaceuticals, Inc. Introduction and Business Overview
10.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Products Offered
10.5.5 BioCryst Pharmaceuticals, Inc. Recent Development
10.6 Ionis Pharmaceuticals, Inc.
10.6.1 Ionis Pharmaceuticals, Inc. Company Information
10.6.2 Ionis Pharmaceuticals, Inc. Introduction and Business Overview
10.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Products Offered
10.6.5 Ionis Pharmaceuticals, Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Hereditary Angioedema Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Hereditary Angioedema Drug Industrial Chain Analysis
11.4 Hereditary Angioedema Drug Market Dynamics
11.4.1 Hereditary Angioedema Drug Industry Trends
11.4.2 Hereditary Angioedema Drug Market Drivers
11.4.3 Hereditary Angioedema Drug Market Challenges
11.4.4 Hereditary Angioedema Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Hereditary Angioedema Drug Distributors
12.3 Hereditary Angioedema Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock